News & Insights

Markets
ABBV

AbbVie Says Canadian Headache Society Backs Atogepant, OnabotulinumtoxinA

December 19, 2024 — 09:21 am EST

Written by RTTNews.com for RTTNews ->

(RTTNews) - AbbVie Inc. (ABBV), Thursday announced that the Canadian Headache Society's newly updated Migraine Prevention Guideline has strongly supported the usage of Atogepant for episodic and chronic migraine treatment, and OnabotulinumtoxinA for chronic migraine treatment.

The recommendations were based on the data supporting the potential benefits of the medications, the company added.

During the pre-market hours, AbbVie's stock is trading at $173, down 0.01 percent on the New York Stock Exchange.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

Markets
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source ->

Stocks mentioned

ABBV

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.